PCT, a development and manufacturing services provider and subsidiary of Caladrius Biosciences, has entered into a global collaboration with Hitachi Chemical that includes licensing, development and equity components. Hitachi Chemical is a global conglomerate with a growing franchise in life sciences, including regenerative medicine. As part of the collaboration, Hitachi has purchased a 19.9% equity interest in PCT for $19.4 million. Caladrius will retain the remaining 80.1% ownership of PCT....